Literature DB >> 35533853

Hybrid SARS-CoV-2 variants.

Farid Rahimi1, Amin Talebi Bezmin Abadi2.   

Abstract

Entities:  

Keywords:  COVID-19; Omicron; Pandemic; Recombinant; SARS-CoV-2

Mesh:

Year:  2022        PMID: 35533853      PMCID: PMC9074379          DOI: 10.1016/j.ijsu.2022.106656

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   13.400


× No keyword cloud information.
Dear Editor, In December 2019, discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2] critically changed the collective mindset about future emergence of an infectious agent with potential to cause an outbreak. The unprecedented spread of SARS-CoV-2 to more than 200 countries in five continents within less than three months in 2020 convinced the World Health Organization to reclassify the epidemic outbreak to a pandemic [3], a classification which has been current when we wrote this letter in mid-April 2022. The global case numbers due to the coronavirus disease 2019 (COVID-19) have been increasing with more than 6.1 million deaths recorded. As the pandemic progressed, distinct peaks of the COVID-19 case numbers coincided with circulation of the genetically evolved SARS-CoV-2 variants in many countries [4,5]. Managing the COVID-19 pandemic, overshadowed by continuously evolving SARS-CoV-2 variants, has been challenging and negatively affected the international healthcare institutions. Thus, understanding the biological rationale for the virus to evolve so rapidly is important for the management of future outbreaks.

SARS-CoV-2 hybrids

Viruses use two major mechanisms to undergo genetic alterations and generate new variants. The first is mainly driven by random occurrence of point-mutations. Many SARS-CoV-2 variants—for example, Alpha, Beta, Gamma, Mu, Delta, and Omicron—have emerged because of point-mutations [5,6]. The second mechanism is “recombination” whereby RNA viruses exchange large segments of genetic material, not necessarily “reciprocally” [7]. Examples of RNA viruses that frequently undergo recombination are coronaviruses, influenza virus, and the human immunodeficiency virus [8]. Recombination was confirmed previously among the viral lineages of MERS-CoV, the coronavirus agent causing the Middle East Respiratory Syndrome [9,10]. By analogy, emergence of the hybrid SARS-CoV-2 variants are expected, though RNA viruses generally are thought to undergo point-mutations more frequently than recombination [7]. The RNA-proofreading enzymes of the RNA viruses are found to be inefficient, thus causing a high rate of errors and low viral fidelity [11]. Coronaviridae however are an exception [11]. Therefore, point-mutations would be a less efficient mechanism to generate new SARS-CoV-2 variants than recombination. Nevertheless, initial high circulation of SARS-CoV-2 and high COVID-19 case numbers worldwide helped the virus to generate successful variants by point mutations. Similarly, observation of several peaks of the COVID-19 cases in five continents during the pandemic suggests that the virus generated highly transmissible and successful variants without gradually losing survival benefits which are expected to occur because of accumulation of deleterious missense mutations. Because recombination mostly occurs between distinct lineages of a virus with more infectious traits and coincides with circulation of highly transmissible viral variants, SARS-CoV-2 is thus highly likely to undergo, and benefit from, recombination as it keeps circulating and evolving. However, the genetic diversity observed in the SARS-CoV-2 genome is less than those of other RNA viruses [12]. An example of a highly transmissible SARS-CoV-2 variant is the Omicron variant detected in South Africa [13,14]. Alpha and Delta variants similarly circulated successfully. Finally, emergence and cocirculation of BA.1 and BA.2, as closely related strains of Omicron, facilitated formation of the hybrid strains following coinfection cases. For example, 47 cases were reported as BA.2-positive shortly after infection with BA.1 in Denmark, thus facilitating occurrence of recombination between the two viral strains [15]. Therefore, the continuity of the pandemic peaks partially armed the new highly transmissible variants to circulate simultaneously. Although early to conclude, we speculate that the new hybrid forms of SARS-CoV-2 followed circulation of Omicron and circulation of the Omicron subvariants that caused high COVID-19 hospitalizations in European and American countries. At ‏the beginning of the COVID-19 pandemic, the possibility of recombination among SARS-CoV-2 variants was questioned [16], and the role of recombination and emergence of new, hybrid viral lineages were not seriously considered. However, generation of the hybrid virus strains should now be considered as a potential mechanism that could aggravate the pandemic by increasing the number of COVID-19-positive cases. Until April 2022, three recombinant forms of the Omicron variants were identified. These include XD, XF, and XE. XD is thought to have resulted from recombination between Delta and the BA.1 lineage of Omicron. XF is a recombinant of BA.1 and the U.K. Delta variants. Interestingly, following the 2022 case surges in the U.K., the U.K. Health Security Agency reported several hybrid forms of SARS-CoV-2 rapidly circulating in the community. The World Health Organization highlights the emergence of the XE variant as a hybrid of the two Omicron subvariants, BA.1 and BA.2 (also termed stealth Omicron). Although the pathological characteristics of XE are not well understood yet, XE is thought to be tenfold more contagious than BA.2. Notwithstanding the mechanisms by which viruses achieve genetic diversity, viral genetic alterations precede evolutionary fitness, including resistance to antiviral drugs or vaccines, high infectivity and transmissibility, immune evasion, and high virulence because deleterious genetic alterations fail to dominate and propagate with the virus [7]. In conclusion, large-scale sequencing projects and alternatively fast and affordable analytical technologies will be valuable for monitoring the progression of the mutated and recombinant SARS-CoV-2 variants globally.

Ethical approval

This article does not require any human/animal subjects to acquire such approval.

Sources of funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author contribution

Farid Rahimi: Conceptualization, data curation, writing – review & editing. Amin Talebi Bezmin Abadi: Conceptualization, data curation, writing – original draft, writing – review & editing. All authors critically reviewed and approved the final version of the manuscript before submission.

Registration Unique Identifying number (UIN)

Name of the registry: Not applicable. Unique Identifying number or registration ID: Not applicable. Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable.

Guarantor

Both authors.

Data statement

Data not available/not applicable.

Provenance and peer review

Not commissioned, internally peer-reviewed.

Declaration of competing interest

None.
  11 in total

1.  Nonhomologous recombination between the hemagglutinin gene and the nucleoprotein gene of an influenza virus.

Authors:  M Orlich; H Gottwald; R Rott
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

2.  MERS-CoV recombination: implications about the reservoir and potential for adaptation.

Authors:  Gytis Dudas; Andrew Rambaut
Journal:  Virus Evol       Date:  2016-01-20

Review 3.  Recombination in viruses: mechanisms, methods of study, and evolutionary consequences.

Authors:  Marcos Pérez-Losada; Miguel Arenas; Juan Carlos Galán; Ferran Palero; Fernando González-Candelas
Journal:  Infect Genet Evol       Date:  2014-12-23       Impact factor: 3.342

4.  Genomic recombination events may reveal the evolution of coronavirus and the origin of SARS-CoV-2.

Authors:  Zhenglin Zhu; Kaiwen Meng; Geng Meng
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

Review 5.  From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants.

Authors:  Vasileios Papanikolaou; Aris Chrysovergis; Vasileios Ragos; Evangelos Tsiambas; Spyros Katsinis; Arezina Manoli; Sotirios Papouliakos; Dimitrios Roukas; Stylianos Mastronikolis; Dimitrios Peschos; Anna Batistatou; Efthimios Kyrodimos; Nicholas Mastronikolis
Journal:  Gene       Date:  2022-01-04       Impact factor: 3.688

Review 6.  SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues.

Authors:  Sinae Kim; Tam T Nguyen; Afeisha S Taitt; Hyunjhung Jhun; Ho-Young Park; Sung-Han Kim; Yong-Gil Kim; Eun Young Song; Youngmin Lee; Hokee Yum; Kyeong-Cheol Shin; Yang Kyu Choi; Chang-Seon Song; Su Cheong Yeom; Byoungguk Kim; Mihai Netea; Soohyun Kim
Journal:  Immune Netw       Date:  2021-12-23       Impact factor: 6.303

7.  Evidence for Recombination as an Evolutionary Mechanism in Coronaviruses: Is SARS-CoV-2 an Exception?

Authors:  Zisis Kozlakidis
Journal:  Front Public Health       Date:  2022-03-17

8.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

Review 9.  Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.

Authors:  Fran Robson; Khadija Shahed Khan; Thi Khanh Le; Clément Paris; Sinem Demirbag; Peter Barfuss; Palma Rocchi; Wai-Lung Ng
Journal:  Mol Cell       Date:  2020-08-04       Impact factor: 17.970

10.  WHO Declares COVID-19 a Pandemic.

Authors:  Domenico Cucinotta; Maurizio Vanelli
Journal:  Acta Biomed       Date:  2020-03-19
View more
  3 in total

1.  The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic - Correspondence.

Authors:  Ranjan K Mohapatra; Venkataramana Kandi; Ashish K Sarangi; Sarika Verma; Hardeep Singh Tuli; Sandip Chakraborty; Chiranjib Chakraborty; Kuldeep Dhama
Journal:  Int J Surg       Date:  2022-06-08       Impact factor: 13.400

Review 2.  Recent review of COVID-19 management: diagnosis, treatment and vaccination.

Authors:  Vivek P Chavda; Suneetha Vuppu; Toshika Mishra; Sathvika Kamaraj; Aayushi B Patel; Nikita Sharma; Zhe-Sheng Chen
Journal:  Pharmacol Rep       Date:  2022-10-10       Impact factor: 3.919

Review 3.  Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.

Authors:  Vivek P Chavda; Qian Yao; Lalitkumar K Vora; Vasso Apostolopoulos; Chirag A Patel; Rajashri Bezbaruah; Aayushi B Patel; Zhe-Sheng Chen
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.